Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04983355
Other study ID # PEPTIDYSS
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 19, 2021
Est. completion date January 25, 2022

Study information

Verified date August 2022
Source Abyss Ingredients
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This interventional, double-blind, randomized, placebo-controlled pilot study aims to evaluate the effect of a dietary supplementation of a fish hydrolysate Peptidyss on sleep quality and anxiety.


Description:

A total of 44 healthy participants (n=22 female, n=22 male) aged 35-60 years inclusive are included into the study, in a cross-over design. The participants will take both products, the fish hydrolysate Peptidyss and the placebo during a period of 4 weeks per product. The total duration of the study per participant is 127 days. The study visits are defined as Screening Visit and Study Inclusion (V0), Pre-Intervention-1-Visit (V1), Post-Intervention-1-Visit (V2), Follow-up-Intervention-1-Visit / Pre-Intervention-2-Visit (V3), Post-Intervention-2-Visit (V4) and Follow-up-Intervention-2-Visit (V5). The 4 weeks between V2 and V3 will serve as a washout phase between Intervention-1 and Intervention-2. No further follow-up visit is planned. The primary objective is to evaluate the efficacy of Peptidyss® on sleep quality. The secondary objectives are to evaluate the efficacy of Peptidyss® on sleep quality, anxiety, perceived stress and quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 45
Est. completion date January 25, 2022
Est. primary completion date January 14, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 35 Years to 60 Years
Eligibility Inclusion Criteria: - Voluntary, written, informed consent to participate in the study - Male or female aged between 35-60 years (inclusive) - Body mass index (BMI) between =18.0 - =35.0 kg/m2 - PSQI score =6 (low perceived sleep quality) - Medical questionnaire at baseline indicates they are healthy in the opinion of the Investigator - Ability of the participant to comprehend the full nature and purpose of the study including possible risks and side effects in the opinion of the Investigator - Agreement to comply with the protocol and study restrictions - Available for all study visits - Agreement to refrain from heavy drinking, late-night alcohol and late-night caffeine during the study - Females of child-bearing potential required to provide a negative urine pregnancy test - Easy access to internet, using email on a daily basis. Exclusion Criteria: - Any known history of a disorder affecting sleep quality, such as narcolepsy, obstructive sleep apnea (OSA), restless leg syndrome (RLS), periodic limb movement syndrome (PLMS) or any condition which contraindicates, in the Investigator's judgement, entry to the study - Self-reported diagnosis of one or more DSM-V axis 1 disorder(s), including but not limited to current depression, anxiety disorder, bipolar spectrum disorder or schizophrenia - Have a significant acute or chronic coexisting illness or any condition which contraindicates entry to the study in the opinion of the Investigator - Previous (last 4 weeks prior to screening) or current intake of psychoactive medication (anxiolytics, sedatives, hypnotics, anti-psychotics, anti-depressants, anti-convulsants, centrally acting corticosteroids, opioid pain relievers) - History of use (within 1 month of the first visit) or current intake (from day of screening onwards) of medication or dietary supplements/oriental herbs that could influence sleep patterns or that the Investigator believes would interfere with the objectives of the study, pose a safety risk or confound the interpretation of the study results (e.g. melatonin, omega-3 dietary supplements, non-steroidal anti-inflammatory drugs (NSAIDS), over-the-counter (OTC) sleep medication (not categorized as sedatives, hypnotics or anti-depressants), anti-coagulants, proton pump inhibitors, anti-histamines, pseudoephedrine, cortisone, beta-blockers) - Self-declared illicit drug users (including cannabis and cocaine) for 3 months prior to screening and during the intervention period - Heavy smoking (>10 cigarettes/day) - High caffeine intake (> 10 cups /day) (or equivalent caffeine intake from other caffeinated drinks e.g., tea, energy drinks), - Work schedule that causes irregular sleep pattern (e.g. night shift) - History of travel to a different time zone within 1 month of the first visit or/and during the study participation - Pregnant or lactating female, or pregnancy planned during intervention period - Not fluent in German - Contraindication or allergy (e.g. fish allergy) to any substance in the investigational product - Participation in another study with any investigational product within 30 days of screening and during the intervention period - Investigator believes that the participant may be uncooperative and/or noncompliant and should therefore not participate in the study.

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
Fish Hydrolysate
The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water. Participants receiving the fish hydrolysate the fourth first weeks will then receive the placebo during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation.
Placebo
The participants take 4 capsules/day of the study product. Two capsules should be consumed orally every morning with breakfast and/or with a glass of (plain, not sparkling) water and not with fruit juice or hot food/drink while ingesting the capsules; and two capsules should be consumed orally every evening with their dinner and/or with a glass of water. Participants receiving the Placebo the fourth first weeks will then receive the fish hydrolysate during another 4 weeks. A wash-out period of 4 weeks is included between each phase of supplementation.

Locations

Country Name City State
Germany daacro GmbH & Co. KG Trier

Sponsors (2)

Lead Sponsor Collaborator
Abyss Ingredients Daacro

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Other Evaluation of salivary cortisol Measured the day and evening prior to each visit 18 weeks
Primary Evaluation of sleep quality Measured with the Pittsburgh Sleep Quality Index (PSQI) at each visit 18 weeks
Secondary Duration of sleep Measured by a daily online diary over the total study 18 weeks
Secondary Evaluation of anxiety Measured with a questionnaire at each visit 18 weeks
Secondary Evaluation of perceived stress Measured with a questionnaire at each visit 18 weeks
Secondary Evaluation of depression, anxiety and stress Measured with a questionnaire at each visit 18 weeks
Secondary Evaluation of quality of life Measured with a questionnaire at each visit 18 weeks
Secondary Evaluation of systolic and diastolic blood pressure Measured at each visit 18 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT05820919 - Enhancing Sleep Quality for Nursing Home Residents With Dementia - R33 Phase N/A
Recruiting NCT04786314 - The Effect of Hot and Cold Water Application on Pregnant Women With Restless Leg Syndrome N/A
Recruiting NCT05775731 - Markers of Inflammation and of the Pro-thrombotic State in Hospital Shift and Day Workers
Recruiting NCT03326765 - Characterizing Sleep Disorders in Children and Adults With Tuberous Sclerosis Complex (TSC) N/A
Completed NCT03673397 - The Acute Effect of Aerobic Exercise on Sleep in Patients With Depression N/A
Completed NCT03903263 - Sleep Disturbances in Dermatology Patients
Not yet recruiting NCT05950932 - Effects of Melissa Extract on Sleep Characteristics Phase 4
Not yet recruiting NCT06012513 - Sleep Disorders and Quality of Life in Patients With Multiple Sclerosis
Completed NCT01463839 - Sleep Disorder and Oral Habits in Children N/A
Completed NCT00940589 - Efficacy of Circadin® 2 mg in Patients With Mild to Moderate Alzheimer Disease Treated With AChE Inhibitor Phase 2
Recruiting NCT06093633 - A Prospective Study to Evaluate the WP in Comparison to PSG in Patients Suspected of Sleep Disorders
Completed NCT06108115 - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder N/A
Completed NCT05511818 - Radicle Rest: A Study of Cannabinoids on Sleep and Health Outcomes N/A
Active, not recruiting NCT04291014 - Light Therapy for PD - Dose Selection N/A
Completed NCT04560595 - Remote Guided Caffeine Reduction N/A
Completed NCT06008470 - Investigation of Respiratory Muscle Strength, Exercise Capacity, Physical Activity and Sleep Quality Level in Individuals With Covid-19 Infection
Recruiting NCT06129942 - Light Therapy in Parkinson's Disease N/A
Recruiting NCT04318067 - Melatonin in ADHD and Sleep Problems Phase 4
Completed NCT03857802 - Efficiency of a Nursing Intervention in Sleep Hygiene N/A
Completed NCT03532269 - Validation of the Sleep Assessment Algorithm in the Medical Application Nightly N/A